Metaxa Cancer Center Hospital Of Piraeus — Clinical Trial Site

20 Registered trials

10 Currently recruiting

Organisation

Metaxa Cancer Center Hospital Of Piraeus

Location

Pireas, Greece

Identifier

ORG-100046125

Address

Botassi 51, 185 37, Greece

Departments

A Internal Medicine-Oncology Department
Department of Medical Oncology
Department of Medical Oncology
Department of Medical Oncology & Hematopoietic Cell Transplant Unit
Gastroenterology Department
Hematology Clinic
Hematology Clinic, Bone Marrow Transplant Unit
Medical Oncology
Medical Oncology Department
Oncology
Oncology/Inte rnal Medicine Department
Pathology - Oncοlogy Clinic

Clinical trials at this site (20)

Search interface

A Phase 2/3 Study of EIK1001 in Combination with Pembrolizumab and Chemotherapy in Participants with Stage 4 Non-Small Cell Lung Cancer. Pending

2025-525013-23-00 Stage 4 (IV) Non-Small Cell Lung Cancer (NSCLC) 4
Study Evaluating Zipalertinib with Chemotherapy for Lung Cancer Patients with Uncommon EGFR Mutations After Surgery Recruiting

2025-521775-31-00 Stage IB-IIIA NSCLC Patients with uncommon EGFR Mutatio 5 2025-11-12
A clinical trial of MK-1084, pembrolizumab, and chemotherapy in people with nonsmall cell lung cancer (MK-1084-013) Recruiting

2024-517337-41-00 Completely resected Stage IIA-IIIB (N2) KRAS G12C mutat 5 2026-05-12
Trial of Trastuzumab Deruxtecan in Combination with Pembrolizumab Versus Pembrolizumab with Platinum-based Chemotherapy in First-line HER2 o… Recruiting

2024-515658-26-00 Unresectable or Metastatic HER2 overexpressing and PD-L 5 2026-01-21
A Phase 2b, Open-Label, Two-cohort Study of Subcutaneous Amivantamab in Combination with Lazertinib as First-Line Treatment, or Subcutaneous… Recruiting

2025-520730-28-00 Common EGFR-Mutated Locally Advanced or Metastatic Non- 4 2025-12-08
A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-line Treatment of PD-L1-high Metastatic Non-small Cell Lung… Recruiting

2024-517780-24-00 Lung Cancer 5 2025-09-18
A Study to Compare the Efficacy and Safety of Vedolizumab With and Without Upadacitinib in Adults With Moderately to Severely Active Crohn's… Recruiting

2023-509391-42-00 Chron's Disease 11 2025-06-02
Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Subjects With Metastatic Colorectal Ca… Recruiting

2022-502352-31-00 Colorectal Cancer (CRC) 5 2025-02-10
Clinical trial comparing MK-2870 given with pembrolizumab to pembrolizumab alone in participants who have had surgery for NSCLC Recruiting

2023-508012-35-00 Newly diagnosed NSCLC with resectable clinical Stage II 5 2024-10-02
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of … Recruiting

2024-518263-35-00 Primary plasma cell leukemia 4 2021-11-23
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Subjects With Progressive Metastatic Castration-… Ended

2024-513968-25-00 Metastatic castration-resistant prostate cancer (mCRPC) 5 2025-04-28
A Phase 3 study of belrestotug plus dostarlimab compared with placebo plus pembrolizumab in previously untreated PD L1 high NSCLC Ended

2023-504753-12-00 Lung Cancer, Non-Small Cell 5 2024-10-01
A Phase 3 Study of Front‑line Platinum Doublet Therapy With Sotorasib Versus Pembrolizumab in PD-L1 Negative KRAS p.G12C Positive Advanced/M… Ended

2022-501863-41-00 Subjects With Stage IV or Advanced Stage IIIB/C Nonsqua 5 2023-11-13
A Study to Evaluate the Efficacy and Safety of Giredestrant Plus Everolimus Compared with the Physician’s Choice of Endocrine Therapy Plus E… Ended

2023-506821-12-00 Estrogen Receptor (ER)-Positive, HER2-Negative, Locally 5 2023-10-12
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A Phase 2 Study of Isatuximab in combination with Pomalidomide and Dexamethasone in MM Patients who received one prior line of therapy conta… Ended

2024-516060-28-00 Multiple myeloma patients who received one prior line o 4 2022-10-17
A study of tucatinib versus placebo in combination with pertuzumab and trastuzumab for subjects with advanced or metastatic HER2+ breast can… Ended

2023-503826-37-00 Unresectable locally-advanced or metastatic HER2+ breas 5 2022-02-11
A Phase 2 Study of Isatuximab in combination with Bortezomib, Cyclophosphamide and Dexamethasone followed by isatuximab and lenalidomide mai… Ended

2024-516061-36-00 Newly diagnosed patients with multiple myeloma and seve 4 2022-07-28
Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants wit… Ended

2023-508443-40-00 Lung Cancer, Non-Small Cell 5 2020-12-18